healthy and had stable tardive dyskinesia for at least six months before the study gave informed consent to participate in this placebo-controlled trial. Pertinent data for each patient are shown in the table.
Tardive dyskinesia is a syndrome of involuntary hyperkinetic movements in the oral, facial, limb, and truncal regions. The pathophysiological basis of tardive dyskinesia is thought to involve the development of dopaminergic receptor hypersensitivity in striatal neurones that results from long-term neuroleptic treatment.' Increasing the neuroleptic dose can suppress tardive dyskinesia temporarily but may aggravate or precipitate drug-induced Parkinsonism. [2] [3] [4] Oxiperomide, a dopaminergic antagonist, reduced levodopa-induced hyperkinesias-which are clinically similar to tardive dyskinesia-in idiopathic Parkinsonism and other spontaneous dyskinesias without producing incapacitating symptoms of Parkinsonism.5 It also inhibited dopaminergic agonist-induced stereotypic behaviour more than the locomotor activity in guinea pigs. 6 These results from clinical and animal studies are consistent with the hypothesis that there are different types of dopaminergic receptors modulating extrapyramidal function.' [6] [7] [8] [9] We, therefore, studied the antihyperkinetic and Parkinsonism effects of oxiperomide in 10 patients with tardive dyskinesia. Furthermore, as eye blinking has been suggested to be associated with extrapyramidal functions,10 we also assessed eye blink rates during the study.
Patients and methods
Ten psychiatric inpatients who were physically healthy and had stable tardive dyskinesia for at least six months before the study gave informed consent to participate in this placebo-controlled trial. Pertinent data for each patient are shown in the table.
Medications, if any, that were being taken at the beginning of the study were continued throughout the entire evaluation. Patient 3 received chlorimipramine 100 mg/day and patient 7 received amitriptyline 100 mg/day. Oxiperomide was given in 5 mg tablet doses twice daily, starting at 10 mg/day and increasing weekly by [5] [6] [7] [8] [9] [10] 
